Executive Profile

John Irving Bell Founder, Deputy Chairman, Development Advisory Board Chairman, Member of The Board of Directors and Member of The Development Advisory Board, Oxagen Limited

Age	Total Calculated Compensation	This person is connected to 7 Board Members in 7 different organizations across 7 different industries. See Board Relationships
60	--

Background

Dr. John Irving Bell, MA, DM, FRCP is Founder of Oxagen Limited. Dr. Bell co-founded Wellcome Trust Centre for Human Genetics at the University of Oxford. Dr. Bell serves as Development Advisory Board Chairman of Oxagen Limited. He serves as Deputy Chairman and Director of Oxagen Limited. He serves as a Director of Isis Innovation Limited. He serves as a Main Board Member of Roche AG. He serves as a Trustee of The Rhodes Trust. He serves as a Member of Scientific Advisory ... Board of Protemix Corporation Limited and AstraZeneca. He serves as Member of Partnership board at Oxford comprehensive Biomedical Research Centre. He served as a Non-Executive Director of Powderject Pharmaceuticals PLC since September 1993. Dr. Bell is a Member of Council of the University of Oxford and a Member of Council for the Medical Research Council. He is President of the Academy of Medical Sciences and Regius Professor of Medicine at Oxford University since 2002, where he directs the largest biomedical research department in the UK. He has particular scientific interests in the genetics of immunologically mediated diseases, specifically rheumatoid arthritis, type 1 diabetes, inflammatory bowel disease and autoimmune thyroid disease. At Stanford, he developed research interests in the area of immunology and genetics with a particular focus on characterising the molecular events associated with susceptibility to autoimmune diseases. He returned to Oxford as a Wellcome Trust Senior Clinical Fellow in 1987 and was elected to the Nuffield Professorship of Clinical Medicine in Oxford in 1992. In 2008, he was made a Fellow of the Royal Society and was made a Knight Bachelor for his services to Medical Science. He was appointed by the Chancellor of the Exchequer in 2006 to Chair the Office for the Strategic Coordination of Health Research (OSCHR), the body responsible to co-ordinate the research functions of the NIHR and the MRC. He serves as a Director of Genentech Inc. He has been a Director of Roche Holding AG since 2001. He went to Oxford as a Rhodes Scholar to train in medicine and undertook postgraduate training in London and at Stanford University.

Corporate Headquarters 91 Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom Phone: 44 1235 443300 Fax: 44 1235 443301 Board Members Memberships Director Genentech, Inc. Founder, Deputy Chairman, Development Advisory Board Chairman, Member of The Board of Directors and Member of The Development Advisory Board Oxagen Limited Director Isis Innovation Limited Member of Partnership board Oxford comprehensive Biomedical Research Centre 1993-N/A Former Non-executive Director PowderJect Pharmaceuticals Plc 2001-Present Director and Member of Audit Committee Roche Holding AG Education Master's Degree Stanford University Unknown/Other Education 1992 The Royal College of Physicians Unknown/Other Education 1975 University Of Alberta Unknown/Other Education 1979 Magdalen College BA 1976 Magdalen College MD 1990 Magdalen College Other Affiliations Advent Venture Partners Genentech, Inc. PowderJect Pharmaceuticals Plc Stanford University Roche Holding AG University Of Alberta The Royal College of Physicians Isis Innovation Limited Magdalen College Protemix Corporation Limited Oxford comprehensive Biomedical Research Centre

Annual Compensation There is no Annual Compensation data available. Stocks Options There is no Stock Options data available. Total Compensation There is no Total Compensation data available.

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.